Universal Health Services (UHS) Is Up 5.6% After Raising Guidance and Expanding Share Buyback Program

• Universal Health Services, Inc. reported strong third-quarter 2025 results, with sales reaching US$4.50 billion and net income rising to US$373 million, alongside increased earnings per share compared to the previous year.
• The company raised its full-year 2025 financial guidance, driven by robust performance and a new Medicaid supplemental payment program, and expanded its share repurchase authorization by US$1.50 billion.
• With leadership raising guidance and approving a larger share buyback, we’ll examine how this signals confidence in Universal Health Services’ future growth prospects.

We've found 16 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Universal Health Services Investment Narrative Recap

To be a Universal Health Services shareholder, you need confidence that ongoing demand for healthcare, especially in behavioral health, will keep supporting earnings despite regulatory, reimbursement, and labor headwinds. The robust Q3 results and raised 2025 guidance are incrementally positive, reinforcing optimism for near-term revenue trends, but operational risks tied to evolving Medicaid policies remain the most important challenge to monitor, and the latest news does not materially alter this risk.

Among recent announcements, the expansion of the company's share repurchase authorization by US$1.50 billion stands out. This move, coupled with ongoing strong earnings and cash flow generation, is particularly relevant as it strengthens the balance sheet and provides added flexibility to pursue future growth opportunities, supporting key catalysts around facility expansion and market positioning.

However, investors should also be mindful: while the Medicaid supplemental payment program supports near-term forecasts, potential future reimbursement cuts could still materially alter the outlook for...

Read the full narrative on Universal Health Services (it's free!)

Universal Health Services is forecast to deliver $19.0 billion in revenue and $1.5 billion in earnings by 2028. This outlook assumes 5.0% annual revenue growth and a $0.2 billion earnings increase from the current $1.3 billion.

Uncover how Universal Health Services' forecasts yield a $243.94 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members project fair values for UHS between US$243.94 and US$652.58, reflecting a wide range across only two investor perspectives. While the company targets growth in behavioral health services, this diverse spread signals that opinions on future performance can differ sharply, explore several viewpoints to inform your own assessment.

Explore 2 other fair value estimates on Universal Health Services - why the stock might be worth over 2x more than the current price!

Build Your Own Universal Health Services Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Universal Health Services research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Universal Health Services research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Universal Health Services' overall financial health at a glance.

Contemplating Other Strategies?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 25 early-stage AI stocks could fund your retirement.
• Rare earth metals are the new gold rush. Find out which 35 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com